Currently, ICIs, particularly those targeting PD-1, CTLA-4, and LAG-3, have demonstrated superior efficacy compared to conventional therapies in treating MM (Figure 3) [25,26,27]. This evidence concerns the gene CTLA4 and Miyoshi myopathy.